Equities research analysts at Robert W. Baird assumed coverage on shares of Maximus, Inc. (NYSE:MMS) in a research note issued to investors on Sunday. The firm set a “neutral” rating on the health services provider’s stock.

A number of other research firms have also commented on MMS. KeyCorp restated a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. ValuEngine lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Canaccord Genuity lowered shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research note on Tuesday, July 4th. BidaskClub lowered shares of Maximus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $62.43.

Shares of Maximus (MMS) opened at 60.39 on Friday. The firm has a 50-day moving average of $60.30 and a 200 day moving average of $61.30. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of 19.36 and a beta of 1.37. Maximus has a 12-month low of $43.69 and a 12-month high of $64.97.

Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The company had revenue of $600.40 million for the quarter, compared to analyst estimates of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. Maximus’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.79 earnings per share. Equities analysts forecast that Maximus will post $3.13 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/05/maximus-inc-mms-now-covered-by-robert-w-baird.html.

In other news, CEO Richard A. Montoni sold 29,203 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $60.38, for a total transaction of $1,763,277.14. Following the transaction, the chief executive officer now directly owns 549,215 shares in the company, valued at $33,161,601.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Andrekovich sold 8,939 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $64.01, for a total transaction of $572,185.39. Following the transaction, the insider now owns 24,583 shares in the company, valued at $1,573,557.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,342 shares of company stock worth $6,677,077. Company insiders own 3.10% of the company’s stock.

Several institutional investors have recently modified their holdings of MMS. Neuburgh Advisers LLC increased its stake in shares of Maximus by 1.9% during the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock worth $105,000 after acquiring an additional 32 shares during the period. Acrospire Investment Management LLC increased its stake in shares of Maximus by 183.3% during the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock worth $106,000 after acquiring an additional 1,100 shares during the period. Glen Harbor Capital Management LLC increased its stake in shares of Maximus by 1.9% during the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock worth $145,000 after acquiring an additional 44 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Maximus by 10.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after acquiring an additional 220 shares during the period. Finally, First Bank & Trust increased its stake in shares of Maximus by 4.2% during the second quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after acquiring an additional 101 shares during the period. Institutional investors and hedge funds own 97.22% of the company’s stock.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Stock Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related stocks with our FREE daily email newsletter.